Literature DB >> 24419408

EGFR mutations in lung cancer: different frequencies for different folks.

Adi F Gazdar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24419408     DOI： 10.1097/JTO.0000000000000063

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  6 in total

1.  Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer.

Authors:  Zhe-Wei Qiu; Jia-Hao Bi; Adi F Gazdar; Kai Song
Journal:  Genes Chromosomes Cancer       Date:  2017-05-04       Impact factor: 5.006

Review 2.  Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance.

Authors:  Wen-Shuo Wu; Yuh-Min Chen
Journal:  J Pers Med       Date:  2014-06-25

3.  Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib.

Authors:  Jupeng Yuan; Nasha Zhang; Longbin Yin; Hui Zhu; Li Zhang; Liqing Zhou; Ming Yang
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

4.  Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival.

Authors:  Venkata Nagarjuna Maturu; Navneet Singh; Amanjit Bal; Nalini Gupta; Ashim Das; Digambar Behera
Journal:  Lung India       Date:  2016 May-Jun

5.  The association between human papillomavirus infection and female lung cancer: A population-based cohort study.

Authors:  Frank Cheau-Feng Lin; Jing-Yang Huang; Stella Ching-Shao Tsai; Oswald Ndi Nfor; Ming-Chih Chou; Ming-Fang Wu; Chun-Te Lee; Cheng-Feng Jan; Yung-Po Liaw
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

6.  Considerations in treating patients with advance lung cancer during the epidemic outbreak of novel coronavirus (SARS-CoV-2).

Authors:  Yangyang Cai; Yinghui Xu; Dongsheng Xu; Yizhuo Wang; Xu Wang; Chao Sun; Ye Guo; Shi Qiu; Kewei Ma
Journal:  Med Oncol       Date:  2020-08-03       Impact factor: 3.064
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.